Harmony Biosciences Holdings Inc [HRMY] stock is trading at $40.00, up 2.22%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The HRMY shares have gain 4.58% over the last week, with a monthly amount glided 11.89%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Harmony Biosciences Holdings Inc [NASDAQ: HRMY] stock has seen the most recent analyst activity on September 10, 2024, when UBS initiated its Buy rating and assigned the stock a price target of $56. Previously, Citigroup started tracking the stock with Buy rating on June 21, 2024, and set its price target to $48. On January 02, 2024, downgrade downgraded it’s rating to Underperform but maintained its price target of $30 on the stock. Goldman downgraded its rating to a Sell and decreased its price target to $31 on September 25, 2023. Berenberg initiated its recommendation with a Buy and recommended $59 as its price target on September 07, 2023. BofA Securities started tracking with a Neutral rating for this stock on April 20, 2023, and assigned it a price target of $35. In a note dated October 14, 2022, Jefferies upgraded an Buy rating on this stock and boosted its target price from $57 to $61.
Harmony Biosciences Holdings Inc [HRMY] stock has fluctuated between $18.61 and $40.10 over the past year. Currently, Wall Street analysts expect the stock to reach $50.67 within the next 12 months. Harmony Biosciences Holdings Inc [NASDAQ: HRMY] shares were valued at $40.00 at the most recent close of the market. An investor can expect a potential return of 26.68% based on the average HRMY price forecast.
Analyzing the HRMY fundamentals
Harmony Biosciences Holdings Inc [NASDAQ:HRMY] reported sales of 656.11M for the trailing twelve months, which represents a growth of 28.76%. Gross Profit Margin for this corporation currently stands at 0.78% with Operating Profit Margin at 0.27%, Pretax Profit Margin comes in at 0.25%, and Net Profit Margin reading is 0.18%. To continue investigating profitability, this company’s Return on Assets is posted at 0.13, Equity is 0.23 and Total Capital is 0.25. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.41.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 39.17 points at the first support level, and at 38.33 for the second support level. However, for the 1st resistance point, the stock is sitting at 40.62, and for the 2nd resistance point, it is at 41.23.
Ratios To Look Out For
For context, Harmony Biosciences Holdings Inc’s Current Ratio is 3.13. As well, the Quick Ratio is 3.09, while the Cash Ratio is 2.16. Considering the valuation of this stock, the price to sales ratio is 3.46, the price to book ratio is 4.22 and price to earnings (TTM) ratio is 20.48.
Transactions by insiders
Recent insider trading involved JEFFREY G DIERKS, Officer, that happened on Sep 30 ’24 when 7175.0 shares were purchased. CHIEF COMMERCIAL OFFICER, Dierks Jeffrey completed a deal on Sep 27 ’24 to sell 200.0 shares. Meanwhile, Officer JEFFREY G DIERKS bought 28971.0 shares on Sep 27 ’24.
